Identidad Institucional CRAI
Logo EdocUR
    • English
    • español
    • português
  •  Work Submission
  •  FAQs
  • English 
    • English
    • español
    • português
  • Login

Contacto

Twitter

Facebook

Youtube

View Item 
  •   Repositorio Institucional EdocUR - Universidad del Rosario
  • Trabajos de grado
  • Escuela de Medicina y Ciencias de la Salud
  • Especializacion en Neurofisiología Clínica
  • View Item
  •   Repositorio Institucional EdocUR - Universidad del Rosario
  • Trabajos de grado
  • Escuela de Medicina y Ciencias de la Salud
  • Especializacion en Neurofisiología Clínica
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Clinical experience of clobazam as add-on treatment in a cohort of adults with epilepsy

  • Exportar citas ▼
    • Exportar a Mendeley
    • Exportar a BibTex
Thumbnail
Date
2016-01-19
Author
Martínez-Micolta, Paula
Lemus, Hernan Nicolás
Advisor
Mayor, Luis Carlos
Share
Citation
URI

http://repository.urosario.edu.co/handle/10336/11819

Summary

Objective: Epilepsy is a common neurologic disorder affecting 1% of the world population with one-third of these patients failing to have seizure control for more than one year. Clobazam is a long-acting benzodiazepine used worldwide for the treatment of epilepsy. This antiepileptic drug has demonstrated great clinical benefits with mild side effects. The objective of this study was to better understand the efficacy of clobazam treatment on adult patients with refractory epilepsy. Design: A retrospective review of 44 adult patients with diagnosis of epilepsy that were seen at our Epilepsy Clinic between January 2014 and May 2015. Setting: An outpatient epilepsy clinic at the Hospital Universitario Fundación Santa Fe de Bogota, Colombia. Participants: 44 adult patients with diagnosis of epilepsy. Measurements: Seizure frequency, adverse effects and the use of concomitant AEDs were reviewed in each of the patient´s clinical charts. Results: The responder rate of patients with clobazam was 52% at 3 months, 50% at 6 months and 55% at 12 month. Seizure freedom rates at 3, 6 and 12 months were 18%, 25% and 25% respectively. Clobazam related adverse events occurred only in four patients (9%) at the end of the twelve months with somnolence being the most common. Conclusion: These findings suggest that clobazam treatment in adult patients with focal or generalized epilepsy is effective and safe. Its use should be considered early when first-line agents fail to provide seizure control.
Subject
add-on treatment ; epilepsy ; antiepileptic drugs ; Clobazam ;

Subject

Enfermedades ;

Show full item record

Collections
  • Especializacion en Neurofisiología Clínica [8]
Política de Acceso Abierto URPortal de Revistas URRepositorio de Datos de Investigación URCiencia Abierta UR
 

 

Browse

All of DSpaceCommunities & CollectionsTitlesAuthorsTypeSubjectsAdvisorBy Issue DateThis CollectionTitlesAuthorsTypeSubjectsAdvisorBy Issue Date

My Account

LoginRegister

Statistics

View Usage Statistics
Política de Acceso Abierto URPortal de Revistas URRepositorio de Datos de Investigación URCiencia Abierta UR